A new anti-aging drug for dogs might hit the market by 2026. San Francisco-based biotech company Loyal is developing LOY-001, a drug designed to help large dogs (40+ pounds) stay healthier as they age.
Loyal’s CEO, Celine Halioua, is leading the charge, working toward FDA approval—a huge step in veterinary medicine. Scientists believe this research could also help us understand aging in humans.
RELATED STORIES
LOY-001 targets metabolism to slow canine aging
LOY-001 focuses on metabolism, which slows with age, leading to lower energy and more health issues. By keeping metabolism in check, the drug aims to help dogs stay healthier for longer.
Aging and metabolism go hand in hand—when metabolism weakens, inflammation and cellular damage increase. LOY-001 could delay this process.
Human metabolism changes in a similar way
Metabolism slows in humans too, starting around age 30. Losing muscle mass speeds up the aging process, which is why strength training is often recommended.
Loyal explains: “Our metabolism changes as we age, leading to reduced health, and dogs are no different. By targeting the underlying mechanisms of aging, Loyal hopes to extend the lifespan of dogs and maintain their quality of life as they age.”
LOY-001 is expected to be available by 2026
If approved, LOY-001 could be on the market in 2026. Loyal has made major progress toward FDA approval.
The company shared: “Today, I’m so proud to announce that Loyal has earned what we believe to be the FDA’s first-ever formal acceptance that a drug can be developed and approved to extend lifespan.”
They added: “From our data, the FDA believes LOY-001 is likely to be effective for large dog lifespan extension in the real world.”
LOY-001 could set a precedent in veterinary medicine
If approved, LOY-001 would be the first drug designed specifically to extend lifespan in dogs. Right now, no medications focus solely on slowing aging—this could change that.
The drug could improve dogs’ quality of life
LOY-001 isn’t just about adding years—it’s about keeping dogs active and healthy longer. It could help with:
- Joint health
- Cognitive function
- Heart health
- Immune support
Large-breed dogs may benefit the most
Larger dogs, like Great Danes, German Shepherds, and Labs, have shorter lifespans. This drug could help them live longer, healthier lives.
Halioua said: “Our research aims to reach millions of dogs across U.S. households.”
Pet owners hope for more time with their dogs
For many, their biggest wish is more time with their pets. Dog owner Sarah Martinez shared: “Watching my dog age faster than necessary breaks my heart. A medication that could give us healthier years together would mean everything.”
Scientists see potential applications for human health
LOY-001’s focus on metabolism has researchers thinking about human applications. If it works for dogs, it could help us understand how to slow aging in people too.
The research deepens our understanding of aging
Loyal’s work adds to aging research, showing similarities between metabolic decline in dogs and humans. Scientists hope these findings could lead to more breakthroughs.
LOY-001 highlights the deep bond between humans and dogs
At the heart of it, this drug is about love. Dogs are family, and the idea of having more years with them is exciting. If science can help them live longer and healthier, why wouldn’t we want that?
And who knows? Maybe one day, this research will lead to similar treatments for people too.
